LEN
53
3
RCL
81
4
PHM
60
6
NTRS
54
4
VMC
62
5
LOW
53
3
ROP
53
2
PFG
36
3
THC
67
2
SRE
52
2
BLK
69
3
M
30
2
ITW
64
2
KHC
20
2
STT
64
4
NDAQ
56
3
PNW
66
3
MMM
30
2
FTI
66
2
LUV
40
2
LEN
53
3
RCL
81
4
PHM
60
6
NTRS
54
4
VMC
62
5
LOW
53
3
ROP
53
2
PFG
36
3
THC
67
2
SRE
52
2
BLK
69
3
M
30
2
ITW
64
2
KHC
20
2
STT
64
4
NDAQ
56
3
PNW
66
3
MMM
30
2
FTI
66
2
LUV
40
2
Financhill
Back

Biomarin Pharmaceutical Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Buy
54

BMRN
Biomarin Pharmaceutical

Last Price:
66.06
Seasonality Move:
13.3%

7 Day Trial

ALL ACCESS PASS

$ 7

U.S. Government Report Alert Tuesday

Discover the Secret Loophole

Biomarin Pharmaceutical Price Quote

$66.06
+0.02 (+0.09%)
(Updated: November 6, 2024 at 5:01 AM ET)

Biomarin Pharmaceutical Key Stats

Buy
54
Biomarin Pharmaceutical (BMRN) is a Buy
Day range:
$65.45 - $66.23
52-week range:
$65.35 - $99.56
Dividend yield:
0%
P/E ratio:
75.91
P/S ratio:
4.71
P/B ratio:
2.33%
Volume:
1.6M
Avg. volume:
1.4M
1-year change:
-17.02%
Market cap:
$12.6B
Revenue:
$2.4B
EPS:
$1.67

How Much Does Biomarin Pharmaceutical Make?

Is Biomarin Pharmaceutical Growing As A Company?

Biomarin Pharmaceutical Stock Price Performance

What Is Biomarin Pharmaceutical 52-Week High & Low?

Biomarin Pharmaceutical Price To Free Cash Flow

Is It Risky To Buy Biomarin Pharmaceutical?

Is Biomarin Pharmaceutical Cash Flow Positive?

  • What Is BMRN Cash Flow From Operations?
    Cash flow from operations (TTM) is $414.7M
  • What Is Biomarin Pharmaceutical’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$518.5M
  • What Is Biomarin Pharmaceutical’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$4.9M

Biomarin Pharmaceutical Return On Invested Capital

  • Is Management Doing A Good Job?
    BMRN return on invested capital is 5.27%
  • What Is Biomarin Pharmaceutical Return On Assets?
    ROA measures how assets are converting to revenues and is 4.69%
  • What Is BMRN Return On Equity?
    ROE is a measure of profitability and is 6.29%

Biomarin Pharmaceutical Earnings Date & Stock Price

Biomarin Pharmaceutical Competitors

Biomarin Pharmaceutical Dividend Yield

Biomarin Pharmaceutical Analyst Estimates

YoY Growth Past Surprise
EPS: 161.91% 14.73%
Revenue: 28.28% 6.03%

Analyst Recommendations

Buy Recommendations: 13
Hold Recommendations: 5
Sell Recommendations: 0
Price Target: 98.52
Upside from Last Price: 49.18%

Major Shareholders

  • How many BMRN shares are owned by institutional investors?
    313.3M BMRN shares are owned by institutional investors
  • How many BMRN shares are owned by insiders?
    2.5M BMRN shares are owned by insiders